David J Cantor, MD, PhD
Assistant Professor of Clinical Medicine (Hematology-Oncology)
Staff Physician, Corporal Michael J. Crescenz VA Medical Center
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
10 South Pavilion
Philadelphia, PA 19104
3400 Civic Center Blvd
10 South Pavilion
Philadelphia, PA 19104
Office: 4849412416
Education:
BA (Philosophy with High Distinction)
The Pennsylvania State University, 2011.
BS (Biochemistry and Molecular Biology with High Distinction and Honors)
The Pennsylvania State University , 2011.
MD, PhD (Medicine and Molecular Oncology)
New York University School of Medicine , 2019.
Permanent linkBA (Philosophy with High Distinction)
The Pennsylvania State University, 2011.
BS (Biochemistry and Molecular Biology with High Distinction and Honors)
The Pennsylvania State University , 2011.
MD, PhD (Medicine and Molecular Oncology)
New York University School of Medicine , 2019.
Selected Publications
Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C.: Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC. Clin Lung Cancer. May 2025.Marmarelis ME, Cantor DJ, Mathew D, McWilliams T, Bauml JB, Hwang W, Zhang J, Singh A, D’Avella C, Davis C, Ye D, Sun L, Ciunci C, Zhang N, Aggarwal C, Cohen RB, Minn A, Wherry J, Langer CJ.: Phase II Study of Pembrolizumab and Itacitinib for Patients with Treatment Naive Metastatic NSCLC Expressing PD-L1: Long-Term Follow Up. World Conference on Lung Cancer Annual Meeting, San Diego, CA. Sep 2024 Notes: "Poster Presentation"
Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Alley E, Cohen RB, Bauml JM, and Langer CJ.: Long-term followup of adjuvant pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer. Texas Lung Conference, Austin, TX. Apr 2024 Notes: "Poster Presentation"
Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Cohen RB, Bauml JM, Langer CJ.: Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC JTO Clin Res Rep 5(6): 100667. Mar 2024 Notes: doi: 10.1016/j.jtocrr.2024.100667.
Cantor DJ, Aggarwal C.: Targeting KRAS-mutated NSCLC – novel TKIs and beyond. Clin Cancer Res 29(18): 3563-3565. Sep 2023.
Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Alley E, Cohen RB, Bauml JM, and Langer CJ.: Long-term followup of adjuvant pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL. Jun 2023 Notes: "Poster Presentation" *Awarded ASCO Merit Award.
Cantor DJ, King B, Blumenberg L, DiMauro T, Aifantis I, Koralov SB, Skok JA, David G.: Impaired Expression of Rearranged Immunoglobulin Genes and Premature p53 Activation Block B Cell Development in BMI1 Null Mice Cell Rep 26(1): 108-118.e4. Jan 2019.
Bainor AJ, Saini S, Calderon A, Polanco RC, Ramirez BG, Monte CM, Cantor DJ, Ernlund A, Litovchick L, David G.: The HDAC-associated Sin3B protein represses DREAM complex targets and cooperates with APC/C to promote quiescence. Cell Rep 25(10): 2797-2807.e8. Dec 2018.
Cantor DJ and David G.: The potential of targeting Sin3B and its associated complexes for cancer therapy. Expert Opin Ther Targets 21(11): 1051-1061, Nov 2017.
Bainor AJ, Deng FM, Wang Y, Lee P, Cantor DJ, Logan SK, David G.: Chromatin-associated protein Sin3B prevents prostate cancer progression by inducing senescence. Cancer Res 77(19): 5339-5348. Oct 2017.